000 04123naa a22005537i 4500
001 UMUN-OA-20261005-PH-034
003 local
005 20261005174914.0
006 m o d
007 cr||||||||||||
008 261005s2014 xx o u000 0 eng d
024 7 _a10.1136/bmj.g4643
_2doi
035 _a(local)EuropePMC:PMC4122754
040 _alocal
_beng
_clocal
041 0 _aeng
100 0 _aA Roy
_eauthor.
245 1 0 _aEffect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. /
_cA Roy; M Eisenhut; R J Harris [and others].
264 1 _a[Place of publication not identified] :
_bBMJ Publishing Group,
_c2014.
300 _a1 online resource (1 article).
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
500 _aPublication type: Review article.
500 _aLinked open-access copy: published version.
506 0 _aOpen access; no subscription required for the linked open-access version.
_fUnrestricted online access
_2star
520 3 _aObjectives To determine whether BCG vaccination protects against Mycobacterium tuberculosis infection as assessed by interferon γ release assays (IGRA) in children. Design Systematic review and meta-analysis. Searches of electronic databases 1950 to November 2013, checking of reference lists, hand searching of journals, and contact with experts. Setting Community congregate settings and households. Inclusion criteria Vaccinated and unvaccinated children aged under 16 with known recent exposure to patients with pulmonary tuberculosis. Children were screened for infection with M tuberculosis with interferon γ release assays. Data extraction Study results relating to diagnostic accuracy were extracted and risk estimates were combined with random effects meta-analysis. Results The primary analysis included 14 studies and 3855 participants. The estimated overall risk ratio was 0.81 (95% confidence interval 0.71 to 0.92), indicating a protective efficacy of 19% against infection among vaccinated children after exposure compared with unvaccinated children. The observed protection was similar when estimated with the two types of interferon γ release assays (ELISpot or QuantiFERON). Restriction of the analysis to the six studies (n=1745) with information on progression to active tuberculosis at the time of screening showed protection against infection of 27% (risk ratio 0.73, 0.61 to 0.87) compared with 71% (0.29, 0.15 to 0.58) against active tuberculosis. Among those infected, protection against progression to disease was 58% (0.42, 0.23 to 0.77). Conclusions BCG protects against M tuberculosis infection as well as progression from infection to disease.Trial registration PROSPERO registration No CRD42011001698 (www.crd.york.ac.uk/prospero/).
540 _aCreative Commons Attribution-NonCommercial. See the linked licence for the applicable terms.
_uhttp://creativecommons.org/licenses/by-nc/3.0/
546 _aIn English.
588 0 _aDescription generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source.
590 _aCourse allocation: B. Sc. Public Health.
653 _aB. Sc. Public Health
653 _aUMUN open access collection
653 _avaccination
655 4 _aReview articles.
700 0 _aM Eisenhut
_eauthor.
700 0 _aR J Harris
_eauthor.
700 0 _aL C Rodrigues
_eauthor.
700 0 _aS Sridhar
_eauthor.
700 0 _aS Habermann
_eauthor.
700 0 _aL Snell
_eauthor.
700 0 _aP Mangtani
_eauthor.
700 0 _aI Adetifa
_eauthor.
700 0 _aA Lalvani
_eauthor.
700 0 _aI Abubakar
_eauthor.
773 0 _tBMJ (Clinical research ed.)
_gVol. 349, (2014), pages/article g4643
_x0959-8138
856 4 0 _uhttps://europepmc.org/articles/PMC4122754
_yRead open-access publication
_zOpen access.
_70
884 _aCourse selection and automated MARC21 enrichment from Europe PMC metadata.
_g20261005
_khttps://europepmc.org/articles/PMC4122754
_qlocal
942 _n0
999 _c1306
_d1306